The Studying the Adhesion Molecule P-selectin in Patients with Ischemic Heart Disease
Background: P-selectin is partially responsible for the adhesion of certain leukocytes and platelets to the
Increased levels of soluble P-selectin in the plasma have also been demonstrated in a variety of cardiovascular
disorders. The aim of this study is to evaluate the role of P-selectin, in development of IHD and possible
use as a biomarker and to study the change in its level after introducing of angiotensin converting enzyme
inhibitor (ACEI) .
Patients and Method: The study involve(49) patients with stable IHD and 51 patient with acute coronary
syndrome and (50) subjects as a control.
They divided into three groups: 1st include subjects with no history of IHD not on (ACEI) as a control
group. 2nd group include patients with history of stable IHD but not receiving any (ACEI)but on B-blocker
therapy. 3rd group include patients with acute coronary syndrome not on ACEI therapy but most of them on
B-blockers as a part of their treatment regimen. (ACEI) (captopril 25 mg twice daily) was given for 1 month
duration for patients in the 2nd and 3rd group for the 2nd and 3rd group we measured the levels of p-selectin
before and after the drug have been introduced
Result: There is increase in level of p-selectin in patients with acute coronary syndrome and to less extent
in patient with stable IHD there is a decrease in the level of platelet P-selectin after introducing of ACEI in
the 2nd and 3rd group.
1. By comparing with control the level of p-selectin is greater in patients with acute coronary syndrome
and to less extent in patient with stable IHD.
2. ACEI administration was associated with significant decrease of the level of p-selectin in patients with
IHD & to a greater extent in patient with acute coronary syndrome.